France to become the first country in Europe to reimburse weight-loss drugs
France to Become the First Country in Europe to Reimburse Weight-Loss Drugs
France to become the first country - France is set to take a pioneering step in Europe by initiating reimbursement for weight-loss medications like Wegovy and Mounjaro starting 15 June. This decision was announced by Health Minister Stéphanie Rist on Thursday, marking a significant shift in the nation's approach to managing obesity. With this move, France will lead the way in Europe, offering coverage for these drugs through its national health insurance system. The policy is expected to provide relief to thousands of patients struggling with weight-related health issues.
A New Era in Obesity Treatment
The minister emphasized her pride in being the first country in the European Union to integrate weight-loss drugs into standard healthcare coverage permanently. “This is a major milestone, as it ensures that patients who need these medications can access them without financial barriers,” Rist stated on French television. She highlighted that while the reimbursement rate is initially set at 65%, most individuals will effectively receive full coverage due to comorbidities such as hypertension or diabetes. These conditions often qualify patients for additional support, allowing them to receive 100% coverage. “For the vast majority of cases, the reimbursement process will be seamless,” she added, underscoring the practical benefits of the policy.
“I am quite proud, because we are the first country in the European Union to provide reimbursement under standard coverage, on a permanent basis,” said Stéphanie Rist. “Officially, reimbursement will be set at 65%, but virtually all patients will be fully covered because they have comorbidities, such as hypertension or diabetes.”
Wegovy, developed by Danish pharmaceutical giant Novo Nordisk, and Mounjaro, produced by Eli Lilly, are part of a newer class of weight-loss drugs known as glucagon-like peptide-1 (GLP-1) receptor agonists. These medications mimic a hormone that naturally suppresses appetite, helping patients achieve significant weight loss. Their mechanism of action has gained attention for its effectiveness in treating obesity, particularly when traditional methods such as diet and exercise fall short. The approval of these drugs for reimbursement comes as part of a broader effort to address the growing prevalence of obesity across the continent.
Patient Access and Treatment Trends
According to estimates, over 70,000 patients in France have already been using Mounjaro as of late January, indicating a strong demand for such therapies. The drug’s availability through prescription since 2024 has allowed healthcare providers to treat patients with obesity, but the recent reimbursement policy will remove a key financial hurdle. Before this change, patients bore the full cost of the monthly injections, which typically ranged around €300. High drug prices have long been a challenge in accessing obesity treatments, not only in France but across Europe and the globe.
France’s decision to reimburse these medications follows a series of policy adjustments aimed at expanding treatment options. In June 2025, the country allowed general practitioners, rather than specialists, to prescribe GLP-1 drugs, further increasing accessibility. This step was crucial in preparing the healthcare system for the broader reimbursement plan, ensuring that a wider range of medical professionals could recommend the therapy without prior restrictions. The move reflects a growing recognition of obesity as a complex, multifaceted condition requiring tailored interventions.
The Scope of Obesity in France and the EU
Obesity is a pressing public health issue in France, affecting approximately 18% of the population, or around 10 million individuals, according to the 2024 National Epidemiological Survey on Overweight and Obesity. This statistic underscores the urgency for innovative solutions to combat the condition. In the broader European Union, the situation is even more widespread, with estimates suggesting that 51% of adults are overweight and 17% are obese, as reported by the European Parliament. These figures highlight the need for systemic changes to improve patient outcomes and reduce the burden of chronic diseases linked to excess weight.
The reimbursement of weight-loss drugs represents a strategic effort to address these statistics head-on. By covering the cost of medications like Wegovy and Mounjaro, France aims to support patients in achieving long-term weight management. This approach is particularly important for individuals with comorbidities, as it reduces the risk of complications from conditions such as diabetes and cardiovascular disease. The policy also aligns with international efforts to standardize obesity care, positioning France as a leader in the region.
Implications for Healthcare and Patients
The impact of this policy extends beyond immediate patient relief. It signals a commitment to integrating advanced therapies into routine healthcare, which could influence other European nations to follow suit. The financial burden on patients has been a critical barrier to treatment, and by covering 65% of costs, France is taking a step toward affordability. For those with comorbidities, the combination of high-risk profiles and existing health conditions means they are likely to qualify for full reimbursement, ensuring consistent access to care.
France’s decision also addresses the broader challenge of rising healthcare expenditures linked to obesity. By reducing the out-of-pocket costs for these medications, the government hopes to mitigate the long-term economic impact of obesity-related illnesses. This approach aligns with the goal of preventative healthcare, as effective weight management can significantly lower the risk of complications and improve overall quality of life. The policy is expected to set a precedent for other countries, potentially accelerating the adoption of similar measures across Europe.
Global Context and Future Outlook
While France leads in this particular initiative, the global landscape for obesity treatment is rapidly evolving. GLP-1 drugs have gained traction worldwide for their efficacy and safety profile, with many countries exploring reimbursement options to expand access. The success of France’s program could serve as a model for other nations grappling with similar challenges. As the population continues to grow in size and complexity, the need for comprehensive, cost-effective interventions becomes increasingly vital.
Looking ahead, the French healthcare system may need to evaluate the long-term effects of this policy. Monitoring patient outcomes, medication adherence, and the overall cost of the program will be essential to ensure its sustainability. Additionally, the minister’s emphasis on standard coverage suggests a desire to normalize these treatments as part of routine care, rather than a specialized option. This shift could redefine how obesity is approached in the coming years, both in France and beyond the continent.
The reimbursement of weight-loss drugs is not just a financial decision but a societal one. It reflects a growing awareness of the role that medication plays in managing obesity and a willingness to invest in long-term health solutions. By making these therapies accessible to a wider population, France is taking a proactive stance in improving public health outcomes and setting a new standard for obesity care in Europe.